NCT02197572View on ClinicalTrials.gov

Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 15, 2014

Primary Completion Date

June 10, 2016

Study Completion Date

February 28, 2019

Conditions
Advanced Solid Tumors
Interventions
DRUG

Sapanisertib

Sapanisertib capsules.

Trial Locations (5)

Unknown

Sarasota

St Louis

The Bronx

Oklahoma City

Dallas

Sponsors
All Listed Sponsors
lead

Calithera Biosciences, Inc

INDUSTRY